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Abstract
Here, we show that forced expression of a B-cell lymphoma 2 (bcl-2) protein lacking residues 1 to 36 at the
N-terminal, including the entire Bcl-2 homology 4 (BH4) domain, determines reduction of in vitro and in vivo human
melanoma growth. Noteworthy, melanoma cells in vivo exhibit markedly increased autophagy, as response to
expression of bcl-2 protein deleted of its BH4 domain. This observation led to the identification of a novel gain
of function for bcl-2 protein lacking the BH4 domain. In particular, upon different autophagic stimuli in vitro,
overexpression of bcl-2 protein deleted of BH4 domain induces autophagosome accumulation, conversion of
microtubule-associated protein 1 light chain 3B-II, reduced expression of p62/SQSTM1 protein, and thereby
enhanced autophagic flux. The relevance of Beclin-1 is evidenced by the fact that 1) the autophagy-promoting
and growth-inhibiting properties are partially rescued by Beclin-1 knockdown in cells expressing bcl-2 protein
lacking the BH4 domain, 2) Beclin-1 only interacts with wild-type but not with deleted bcl-2, and 3) BH4 domain
removal from bcl-2 protein does not influence in vitro and in vivo growth of tumor cells expressing low levels
of endogenous Beclin-1. These results provide new insight into molecular mechanism of bcl-2 functions and
represent a rationale for the development of agents interfering with the BH4 domain of bcl-2 protein.
Neoplasia (2013) 15, 315–327
Introduction
Even though the B-cell lymphoma 2 (bcl-2) family proteins are critical
regulator of apoptosis, they have also multiple apoptosis-independent
functions that are involved in several phenomena including cell prolif-
eration [1–3], tumor metastatization [4,5], angiogenesis [6–9], and
autophagy [10].
Autophagy can be induced by different conditions, such as nutrient
deprivation, chemotherapy, and hypoxia. It is controlled by conjugation
of the ubiquitin-like protein microtubule-associated protein 1 light chain
3 (LC3) with phosphatidylethanolamine through an enzymatic cascade
catalyzed by autophagy-related proteins. Phosphatidylethanolamine-
conjugated LC3, known as LC3II, serves as a recognition site for
LC3-binding chaperones, such as p62/SQSTM1, that deliver their cargo
to autophagosomes [11,12].
Abbreviations: Bcl-2, B-cell lymphoma 2; BH, Bcl-2 homology; LC3B, microtubule-
associated protein 1 light chain 3B; EGFP, enhanced green fluorescent protein; sh, short
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Alterations in the pathways regulating autophagy may result in can-
cer development and progression [13]. A growing body of evidence
indicates that antiapoptotic bcl-2 family members (bcl-2, bcl-xL,
and mcl-1) inhibit induction of autophagy triggered by several stimuli
through binding and blocking Beclin-1, a Bcl-2 homology 3 (BH3)–
only protein with autophagy-promoting function [10]. However, bcl-2
expression silencing has been shown to induce autophagy [14], while
bcl-2 inhibitors are able to trigger both Beclin-1–dependent and Beclin-
1–independent autophagy [15].
Bcl-2 family members are characterized by the presence of four
domains, BH1, BH2, BH3, and BH4: while some proteins possess
up to four BH domains, other have either three (BH1, BH2, and
BH3) or only one domain (BH3). The ability of many bcl-2 family
members to form homodimers as well as heterodimers could be im-
portant for both activation and neutralization of specific functions.
Further, bcl-2 protein has been identified as a caspase substrate, and
its cleavage at the N-terminal appears to inactivate bcl-2 function in
the apoptotic pathway [16]. Recently, we also demonstrated the mecha-
nism by which bcl-2 through its BH4 domain regulates HIF-1–
dependent angiogenesis that is independent of antiapoptotic and
prosurvival function of bcl-2 [17].
By using in vitro human melanoma, lung, and colon carcinoma
cell cultures and in vivo mouse xenograft models expressing bcl-2
protein wild type (wt) or deleted of BH4 domain, in this study we




Human M14, A375SM-SC1, and JR8 melanoma, HT29 colon,
and H1299 lung carcinoma cell lines were transfected and cultured
as previously reported [17,18]. Control, bcl-2 wt, and bcl-2 deleted
of its BH4 domain (bcl-2/BH4del) overexpressing clones derived
from the M14, A375SM-SC1, H1299, JR8, and HT29 cells after
stable transfection were cultured in the presence of puromycin (puro,
1 μg/ml; Sigma-Aldrich, St Louis, MO). For enhanced green fluo-
rescent protein (EGFP)–LC3B [19], mRFP-EGFP-LC3B (ptfLC3,
Addgene, plasmid 21074), luciferase (pGL4.50-Luc2; Promega,
Madison, WI), and shBeclin-1 subclones, a polyclonal population
of stably transfected cells were cultured in the presence of geneticin
(800 μg/ml; Sigma-Aldrich).
Treatments
Autophagy was induced by serum starvation, exposure to hypoxia
(1% oxygen), or rapamycin (1 μM; Sigma-Aldrich). For some experi-
ments, cells were treated with bafilomycin A1 (2.5 nM; Santa Cruz
Biotechnology, Santa Cruz, CA), chloroquine (25 μM), hydrogen per-
oxide (H2O2, 50 μM, 24 hours), acridine orange (Sigma-Aldrich), and
cisplatin (CDDP, 20 μM, 48 hours; Pfizer, New York, NY). Experi-
ments by using z-VAD-fmk (50 μM; BD Pharmingen International,
SanDiego, CA) were performed, adding the inhibitor to the cells 1 hour
before treatment and maintained in the medium thereafter. Cell pro-
liferation, cell colony–forming ability, apoptosis, and progression of
cells through cell cycle phases were analyzed as previously described
[20,21]. Oligodeoxynucleotide treatment was performed as previously
reported [21].
Analysis of Autophagy
Evaluation of autophagosomal structures was obtained by fluores-
cence microscopy observing LC3B puncta in EGFP-LC3B or mRFP-
EGFP-LC3B expressing cells or through LC3B antibody (Cell Signaling
Technology, Danvers, MA) staining. For some experiments, a primary
antibody against p62/SQSTM1 (Santa Cruz Biotechnology) was also
used. Preparation of microscopy slides was performed as previously
described [22]. The images were scanned under a ×63 oil immersion
objective, and to avoid bleed-through effects, each dye was scanned in-
dependently by using a Leica DMIRE2 microscope equipped with a
Leica DFC 350FX camera, elaborated by a Leica FW4000 deconvo-
lution software (Leica, Solms, Germany) and processed using Adobe
PhotoShop software. Acridine orange (1 μg/ml, 15 minutes) staining
was used to detect acidic vesicular organelles (AVOs) in live cells.
Orange-positive cells were quantified by flow cytometric analysis. Cells
with more than 10 puncta were considered autophagy positive.
Immunoprecipitation, Western Blot, and
Immunohistochemical Analyses
Immunoprecipitation, Western blot, and immunohistochemical
analyses were performed as previously reported [22,23]. For Western
blot analysis, 40 μg of total proteins was loaded unless otherwise in-
dicated. Antibodies against bcl-2, p62/SQSTM1, HA epitope (Santa
Cruz Biotechnology), Beclin-1 (Cell Signaling Technology), poly
(ADP-ribose) polymerase (PARP; BD Pharmingen International),
β-actin, LC3B, bromodeoxyuridine (BrdU; Sigma-Aldrich), Ki67
(Novus Biologicals, Littleton, CO), and HSP72/73 (Calbiochem,
EMD Biosciences, La Jolla, CA) were used.
For morphologic and immunohistochemical analyses, tumors
obtained 40 days after intramuscular (i.m.) injection were placed in
10% buffered formalin or zinc fixative for 24 hours, dehydrated,
and embedded in paraffin. Four-micrometer-thick serial sections were
stained with hematoxylin and eosin for the evaluation of cellularity and
mitotic index or used for immunohistochemistry. Semiquantitative
evaluation of immunoreactions was performed as reported [24].
In Vivo Tumorigenicity
In vivo experiments were performed as previously reported [24],
injecting i.m. 5 × 106 cells (analysis of tumor growth) or from 5 ×
105 to 5 × 106 cells for tumor take. For some experiments, BrdU
(100 mg/kg) was administrated intraperitoneally 2 hours before animal
sacrifice. Tumor sections were stained with anti-BrdU monoclonal
antibody. For in vivo bioluminescence experiments, animals were sub-
cutaneously injected with 2 × 106 cells and luciferase activity was quan-
tified by IVIS Imaging System 200 (Caliper Life Sciences, Hopkinton,
MA). Mice were anesthetized with a combination (i.m., 2 mg/kg) of
tiletamine-zolazepam (Telazol, Virbac, Carros, France) and xylazine
(Xilazyne/Rompun, Bayer, Leverkusen, Germany) and then injected
intraperitoneally with 150 mg/kg D-luciferin (Caliper Life Sciences)
and imaged 10 to 15 minutes after injection. Data were acquired and
analyzed using Living Image software version 3.0 (Caliper Life Sciences).
Statistical Analysis
Differences between groups were analyzed with a two-sided paired or
unpaired t test by use of GraphPad Prism 3.00 (GraphPad Software,
San Diego, CA). Results were considered to be statistically signifi-
cant if P < .05 (*, #). Experiments were replicated three times unless
otherwise indicated.
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Results
Deletion of BH4 Domain Affects In Vitro Autophagy of
M14 Melanoma Cells
Bcl-2 protein has been found to inhibit autophagy [10]. We first
investigated whether knockdown of bcl-2 expression leads to autophagy
induction in M14 melanoma cells. To this purpose, M14 cells stably
expressing EGFP-LC3B fusion protein were treated with oligonucleo-
tide antisense (AS bcl-2) or with a control oligonucleotide sequence for
6 hours and the presence of punctate structures was evaluated after
48 hours. Formation of punctate structures with EGFP-LC3B fusion
protein is a well-characterized marker to visualize autophagosomes
and represents the accumulation of a membrane-bound form of
LC3B-II on autophagic vesicles [25]. As reported in Figure W1, treat-
ment with AS bcl-2 resulted in an increase in the characteristic redistri-
bution of EGFP-LC3B, from a diffused staining to punctate vesicular
structures, concomitantly to a decreased expression of bcl-2 protein.
These results suggest that silencing of bcl-2 induces autophagy in
Figure 1. Deletion of BH4 domain from bcl-2 protein in M14 and H1299 cells increases autophagosome formation in response to
autophagic stimuli. (A) Western blot analysis of bcl-2 protein expression in M14 control clone (puro) and its derivatives overexpressing
bcl-2 wt (Bcl-2wt) or deleted of BH4 domain (BH4del). β-Actin is shown as loading and transferring control. Two bands, indicative of the
higher endogenous full-length and shorter exogenous bcl-2 protein, were observed in cells overexpressing bcl-2 deleted of BH4 region,
while a single high band was observed in control cells (puro, transfected with empty vector) and in cells overexpressing bcl-2 wt protein.
RepresentativeWestern blot of two independent oneswith similar results is shown. (B) AVOs inM14 control clone and its derivatives grown
in complete media, under serum starvation or exposed to rapamycin or hypoxia for 48 hours. (C) Representative images of fluorescence
microscopy and (D) quantification of cells positive for autophagosomal structures in M14 and H1299 control and derivative clones stably
transfected with EGFP-LC3B vector grown as reported in B. (B, D) The results represent the average ± SEM of three independent experi-
ments. *P < .05, comparison between control cells and bcl-2 wt or mutant clones; #P < .05, comparison between wt and mutant bcl-2.
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M14 cells and further support the observation that bcl-2 confers protec-
tion to cells against autophagy [14,26].
Next, we studied the involvement of BH4 domain of bcl-2 protein in
autophagy. To this purpose, M14 melanoma clones stably overexpress-
ing bcl-2 protein wt or deleted of residues 1 to 36 at the N-terminal
(bcl-2/BH4del; Figure 1A), previously characterized for their response
to apoptotic and angiogenic stimuli [17], were used. We evaluated the
response of M14 and its derivatives to canonical inducers of autophagic
process, such as serum starvation, rapamycin, and hypoxia (Figure 1,
B–D). Under basal conditions, no significant differences were ob-
served in the different clones in terms of AVO formation, a hallmark
of autophagic cells (Figure 1B). After a 48-hour serum starvation, about
15% of control cells showed prominent red fluorescence, while a lower
percentage of AVO-positive cells (about 8%) was observed after bcl-2 wt
overexpression.However, approximately 35%of AVO-positive cells were
evidenced when overexpressing bcl-2/BH4del protein. Time-dependent
increase of AVO formation was also observed after exposure to 8- to
24-hour serum starvation (data not shown). Increased autophagy was also
evidenced in bcl-2/BH4del expressing cells compared to control clones
in response to rapamycin and hypoxia, while bcl-2 wt overexpression
reduces the number of AVO-positive cells induced by both stimuli.
As shown in Figure 1, C and D, under growth in complete media
M14 control cells expressing EGFP-LC3B showed diffuse cytoplasmic
distribution of green fluorescence similar to that of bcl-2 wt clone,
whereas an increase in the characteristic redistribution of EGFP-LC3B,
from a diffused staining to punctate vesicular structures, was observed
in the clone expressing bcl-2/BH4del.
Likewise, upon starvation or exposure to rapamycin or hypoxia, a
significant increase in punctate vesicular structures was observed in
clone expressing bcl-2/BH4del when compared to control and bcl-2
wt overexpressing transfectants. Similar results were also observed in
EGFP-LC3B expressing H1299 lung carcinoma cells transfected with
expression vectors encoding bcl-2 wt or bcl-2/BH4del (Figure 1, C and
D), thus indicating that BH4 domain deletion from bcl-2 protein can
induce autophagosome accumulation in different tumor histotypes.
Concurrent with autophagosome maturation, cargo incorporation
occurs, and it can be monitored by analyzing p62/SQSTM1 and
LC3B protein colocalization. As reported in Figure 2A under growth
in complete media, p62/SQSTM1 and EGFP-LC3B proteins are pre-
dominantly diffuse in M14 control and bcl-2 wt overexpressing trans-
fectants, whereas punctate structures colocalized with p62/SQSTM1
bodies in cells expressing bcl-2/BH4del, indicating incorporation of
specific p62/SQSTM1-labeled cargo into autophagosomes. Likewise,
after starvation, these structures are more evident in cells expressing
bcl-2/BH4del than in control and bcl-2 wt transfectants.
Next, to monitor the activation of autophagic flux, we measured
the conversion of LC3B-I to LC3B-II and the level of p62/SQSTM1
protein by Western blot analysis. As shown in Figure 2B, the level
of LC3B-II was increased upon starvation in both control (about
two-fold) and bcl-2/BH4del expressing cells (about three-fold), being
the induction more evident in the latter ones. On the contrary, the level
of LC3B-II slightly changed in cells stably overexpressing bcl-2 wt
exposed to serum starvation (about 1.4-fold). At the same time, a strong
decrease of p62/SQSTM1 protein expression was observed in control
Figure 2. Deletion of BH4 domain from bcl-2 protein enhances autophagic flux. (A) Immunofluorescence staining of p62/SQSTM1 protein
in M14 control clone (puro) and its derivatives overexpressing bcl-2 wt (Bcl-2wt) or deleted of BH4 domain (BH4del) stably transfected with
EGFP-LC3B vector grown in complete media or under serum starvation (48 hours). Representative images are shown. Western blot analysis
of LC3B-I/II (B) and p62/SQSTM1 (C) protein expression in M14/EGFP-LC3B derivatives grown in complete media or under serum starvation
for 48 hours, in the presence or absence of chloroquine (25 μM). Western blots, representative of three independent experiments with simi-
lar results, are shown. β-Actin is shown as loading and transferring control. LC3B-II levels are quantified by densitometric analyses and the
fold of increase relative to control is presented. (D) Representative images of fluorescence microscopy of H1299 control (puro) and derivative
clones (Bcl-2wt and BH4del) stably transfected with mRFP-GFP-LC3B constructs grown under serum starvation (24 hours).
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cells and in cells expressing bcl-2/BH4del in response to starvation but
not in cells stably overexpressing bcl-2 wt (Figure 2C).
To determine whether the increase of LC3B-II conversion observed in
cells expressing bcl-2/BH4del was due to autophagy induction or to in-
hibition of autophagic process completion, we used chloroquine, which
blocks late stage of autophagy. As reported in Figure 2B, chloroquine
causes an increase in LC3B-II conversion in cells incubated in complete
growth media regardless bcl-2 protein status, reflecting the basal level of
autophagy of these cells. This effect is more evident when cells were
exposed to serum starvation, confirming that starvation can induce a
complete autophagic flux in these cells. Bafilomycin A1, another inhib-
itor of late-stage autophagy, produced superimposable data (data not
shown). Similar results were also obtained by analyzing the percentage
of cells with punctate vesicular structures in EGFP-LC3B expressing
H1299 cells and its derivatives. The combination of chloroquine with
serum starvation in cells expressing bcl-2/BH4del resulted in a much
stronger accumulation of EGFP-LC3 puncta than chloroquine alone,
compared to control and bcl-2 wt overexpressing cells (data not shown).
To confirm the induction of a complete autophagic flux, we used
a pH-sensitive, double-tagged mRFP-GFP-LC3B reporter to deter-
mine the autophagosome maturation and autolysosome formation in
H1299. As GFP but not mRFP fluorescence is lost in acidic compart-
ments, mRFP-GFP-LC3B labels nonacidic autophagosomes as yellow
fluorescence (positive for both green and red) but acidic autophagoly-
sosomes as red fluorescence only [27]. The increase of red fluorescence
observed under serum starvation indicates that autolysosome matura-
tion proceeds normally; moreover, such red fluorescence was higher
in control cells and in cells that express bcl-2/BH4del protein than in
bcl-2 wt transfectants, confirming that autophagic flux is inhibited
in bcl-2 wt overexpressing cells (Figure 2D). All together these data
indicate that deletion of bcl-2 protein induces a significant level of
autophagy rather than blocking the basal level of autophagosome
degradation in M14 cells.
Because bcl-2 protein devoid of its BH4 domain can be generated
by different agents [16,28], several conditions have been used to gene-
rate cleavage of endogenous bcl-2 protein in M14 cells. As reported
by Western blot analysis in Figure W2A, in addition to the expected
26-kDa band corresponding to the bcl-2 protein, a bcl-2 cleavage
product of about 23 kDa was evident in floating cells after exposure
to H2O2 or CDDP or when cells were left to die 6 days after seeding
in high cell density condition. Under these conditions, bcl-2 cleavage
product was absent or barely detectable in adherent cells in both
untreated cells and cells exposed to stress condition. As expected, bcl-2
cleavage occurred concomitantly with caspase activation as monitored
Figure 3. Deletion of BH4 domain from bcl-2 protein in M14 cells reduces tumorigenicity. In vitro (A) cell proliferation and (B) clonogenic
ability and (C) in vivo tumor growth of M14 control (puro) and its derivatives overexpressing bcl-2 wt (Bcl-2wt) or deleted of BH4 domain
(BH4del). (A) The results represent the average ± SD of three independent experiments. (B) Three representative dishes of six are
shown. (C) The results represent the average ± SD of one representative of three experiments with similar results. (D) Bioluminescence
imaging of tumor-bearing mice 6 days after injection of luciferase expressing M14 control (puro) and its derivative clones. *P < .05,
relative to control cells.
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by PARP cleavage. Notably, a concomitant increased expression of
LC3B-II and decreased expression of p62/SQSTM1 proteins reflecting
an autophagy induction was observed (Figure W2A). Importantly,
PARP cleavage, increase of LC3B-II, and decreased expression of p62/
SQSTM1 protein were completely inhibited by pretreatment of M14
cells with a pan-caspase inhibitor z-VAD-fmk before CDDP treatment
(Figure W2B). Notably, in the presence of CDDP and pan-caspase
inhibitor, the number of floating cells was irrelevant and no generation
of the bcl-2 fragment was observed in the cell extracts from pooled
adherent and floating cells (data not shown). These data demon-
strated that induction of apoptosis in M14 cells is paralleled by caspase-
dependent cleavage of bcl-2 and induction of autophagy.
Deletion of BH4 Domain Affects In Vitro Cell Proliferation
and In Vivo Tumorigenicity
We next evaluated the effect of bcl-2/BH4del expression on in vitro
and in vivo M14 cell growth. As reported in Figure 3A, starting from
day 4 of growth two clones expressing bcl-2/BH4del showed a sig-
nificant reduction in cell proliferation, when compared to both control
and bcl-2 wt overexpressing clones (P < .05). We next performed a
BrdU pulse/chase experiment to follow the kinetic of cell cycle progres-
sion (FigureW3A). The exit of cells out from S phase is quite similar for
all the clones analyzed. However, the reappearance of BrdU-positive
cells into the S phase began at about 12 hours for control and cells
expressing bcl-2 wt, while cells expressing bcl-2/BH4del reentered into
the S phase about 18 hours after BrdU pulse, suggesting a cell cycle
delay in latter cells. No significant apoptosis was observed up to day 8
of cell growth regardless bcl-2 status (Figure W3B).
We also assessed the ability of M14 cells and its derivatives to form
colonies (Figure 3B). While an increased number of colonies was
observed after bcl-2 overexpression, a dramatic reduction in colony-
forming potential was evidenced in cells expressing bcl-2/BH4del as
compared with control transfectants.
To evaluate the effect of ectopic expression of bcl-2/BH4del in
in vivo M14 tumorigenicity, parental cells and their derivatives were
injected into nude mice. After i.m. injection of 5 × 106 M14 cells,
Figure 4. Deletion of BH4 domain from bcl-2 protein in A375SM-SC1 cells reduces tumorigenicity. (A) Western blot analysis of bcl-2
protein expression in human A375SM-SC1 melanoma cells stably transfected with empty vector (puro) or with vectors encoding bcl-2 wt
protein (Bcl-2wt) or bcl-2 protein deleted of BH4 domain (BH4del). (B) In vitro cell proliferation, (C) clonogenic ability, (D) in vivo tumor
growth, and (E) tumor incidence of A375SM-SC1 cells and its derivatives. (B) The results represent the average ± SD of three indepen-
dent experiments. (C) Three representative dishes of six are shown. (D, E) Representative experiments of two independent ones with
similar results are shown. *P < .05, relative to control cells.
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all animals developed tumors and the analysis of the median time
of tumor appearance revealed that mice injected with control and
bcl-2 wt overexpressing cells began to develop tumors about 10 days
after cell implant, similarly to mice injected with cells expressing
bcl-2/BH4del. As Figure 3C illustrates, only about 37 days after cell
implant, tumors derived from cells overexpressing bcl-2 wt had a
significant growth advantage when compared with tumors derived
from control cells (P < .05), whereas tumors derived from cells ex-
pressing bcl-2/BH4del exhibited tumor growth rates lower than
tumors derived from both control cells and cells expressing bcl-2 wt,
already evident at early stage of growth (P < .05, starting from days 26
and 29 for BH4del6 and BH4del5 clones, respectively).
The tumor-suppressor activity of bcl-2/BH4del protein is further
illustrated by tumor incidence when mice were injected with a lower
number of cells. In particular, 8 weeks after injection of 5 × 105 cells,
only about 20% of mice injected with bcl-2/BH4del expressing cells
developed tumors, whereas the percentage reached 100% in the mice
injected with control or bcl-2 wt overexpressing cells. Moreover, the
analysis of the median time of tumor appearance revealed that mice
injected with 5 × 105 bcl-2/BH4del expressing cells began to develop
tumors about 63 days after injection, whereas the same number of
control and bcl-2 wt overexpressing cells resulted in tumors after
about 48 days.
When mice were subcutaneously injected with 2 × 106 M14 cells
stably expressing both luciferase and wt or deleted bcl-2 protein, im-
aging analysis evidenced that the luminescent signal was stronger in
control and bcl-2 wt xenografts than in the tumors derived from cells
expressing bcl-2/BH4del (Figure 3D). Removal of BH4 domain from
bcl-2 protein in A375SM-SC1, another human melanoma cell line,
also reduced in vitro and in vivo tumorigenicity (Figure 4, A–E).
M14 Xenografts Carrying Bcl-2/BH4del Protein Show
Decreased Proliferation and Increased Autophagy
To determine whether reduced in vivo tumor growth was paralleled
by reduced expression of the proliferation marker Ki67, we performed
immunohistochemical analyses of tumor sections derived from M14
cells and its derivatives. As reported in Figure 5, A and B, while tumors
overexpressing bcl-2 wt protein showed a significantly higher num-
ber of Ki67-positive cells than those found after implantation of
control cells, tumors carrying bcl-2/BH4del protein showed a sig-
nificantly reduced number of cells expressing Ki67 when compared
to both control and bcl-2 wt overexpressing xenografts. A decreased
Figure 5. M14 xenografts carrying bcl-2 protein lacking the BH4 domain show decreased proliferation and increased autophagy.
(A) Representative images and (B) quantification of Ki67 immunostaining in tumor xenografts from M14 control (puro) and its derivatives
overexpressing bcl-2 wt (Bcl-wt) or deleted of BH4 domain (BH4del). Original magnification, ×200. Histochemical analysis of (C) mitosis
(hematoxylin and eosin) and (D) BrdU staining in xenografts from M14 control (puro) and its derivatives. (B–D) The results represent the
average ± SD of three independent experiments. (E) Western blot analyses of bcl-2 and LC3B-I/II protein expression in tumor xenografts
obtained 40 days after i.m. implantation of M14 parental (puro) and its derivatives. β-Actin is shown as loading and transferring control.
A representative Western blot of two independent ones with similar results is shown. (F) Quantification of LC3B-II/LC3B-I protein ratio by
densitometric evaluation of Western blot analysis presented in E. *P < .05, relative to control cells.
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number of mitotic figures (Figure 5C ) and a reduced in vivo BrdU
(Figure 5D) incorporation were also found in tumors carrying bcl-2/
BH4del protein when compared to both control and bcl-2 wt over-
expressing xenografts.
We next examined the conversion of LC3B-I to LC3B-II protein in
M14 tumor xenografts (Figure 5, E and F ) by Western blot analysis.
Notably, increased LC3B-II/LC3B-I ratio was observed in tumors
derived from cells expressing bcl-2/BH4del when compared to both
control and bcl-2 wt overexpressing xenografts. Moreover, all bcl-2–
overexpressing tumors maintained a high level of wt or deleted bcl-2
protein, confirming the stability of ectopically expressed bcl-2 in vivo
(Figure 5E).
Deletion of α1 Helix of Bcl-2 Does Not Affect In Vivo
Tumor Growth of M14 Cells
BH4 domain of bcl-2 protein is characterized by the presence of
a secondary α helix structure (α1 helix). To ascertain whether the
deletion of the entire BH4 domain (residues 1–36) or of just the α1
helix (residues 1–22) of bcl-2 was necessary to delay tumor growth,
we assessed the effect of the overexpression of a bcl-2 mutant deleted
of residues 1 to 22 including the α1 helix of BH4 domain (bcl-2 Δα1)
on in vivo tumor growth (Figure 6, B–D). This deletion mutant has
been demonstrated to be defective in apoptosis inhibition but com-
petent for autophagy suppression, and it has been described to pro-
mote cell growth as efficiently as bcl-2 wt in MCF7 breast cancer
[29]. Mixed population of M14 human melanoma cells stably trans-
fected with expression vectors encoding human wt bcl-2, bcl-2 Δα1,
or bcl-2/BH4del were obtained. Upon starvation, an increase of AVO-
positive cells was observed only in control (about 17%) and in bcl-2/
BH4del mutant (about 49%) compared to the cells expressing bcl-2
wt protein, while as expected and previously reported [29], bcl-2 Δα1
expressing cells inhibited starvation-induced AVOs as effectively as
the cells expressing bcl-2 wt protein (about 4%; Figure 6A), thus con-
firming that bcl-2 Δα1 protein retains the antiautophagic properties
of wt bcl-2.
As shown in Figure 6B, we found that after i.m. injection of 5 ×
106 cells, tumors derived from control cells and cells expressing bcl-2
wt and bcl-2 Δα1 protein cells do not show significant differences in
growth rate until day 30. However, tumors derived from cells express-
ing bcl-2/BH4del, consistent with the findings reported in Figure 3,
Figure 6. Deletion of α1 helix of bcl-2 does not affect in vivo tumor growth of M14 cells. (A) AVOs in cells grown in complete media or under
serum starvation (hours) and (B) in vivo tumor growth of M14 control (empty) and its derivatives overexpressing bcl-2 wt (Bcl-2wt) or deleted
of amino acid residues 1 to 36 (BH4del) or 1 to 22 (α1del). (A) The percentage of cells with prominent red fluorescence is shown. (A, B)
Representative experiments of two independent ones with similar results are shown. (C) Immunohistochemical analysis and (D) semi-
quantitative evaluation of p62/SQSTM1 protein in M14 derivative xenografts 40 days after tumor implant. Original magnification, ×400.
Results are reported as means ± SEM. Representative images are shown. *P < .05, relative to control cells.
322 Role of BH4 Domain of Bcl-2 in Tumor Growth Trisciuoglio et al. Neoplasia Vol. 15, No. 3, 2013
C and D, exhibited lower tumor growth rates when compared to con-
trol cells. Tumor tissue sections were also examined for p62/SQSTM1
expression by immunohistochemistry. As shown in Figure 6, C and
D, bcl-2/BH4del tumor xenografts showed a weakly positive p62/
SQSTM1 protein expression, whereas a moderate to strong immuno-
reactivity for p62/SQSTM1 was observed in bcl-2 Δα1 and bcl-2 wt
overexpressing xenografts as documented by semiquantitative evaluation
(Figure 6D).
Overall, these results reveal that the deletion of different lengths of
N-terminal from bcl-2 protein can differently affect tumor growth.
Bcl-2 Protein Lacking the BH4 Domain Strongly Impairs
the Binding between Bcl-2 and Its Interacting Proteins
Bcl-2 protein modulates either apoptosis or autophagy through its
interaction with proapoptotic and Beclin-1 proteins, respectively
[10,29]. To investigate whether BH4 domain is required for bcl-2
interaction with Beclin-1, we tested the ability of bcl-2 protein deleted
of BH4 domain to associate with this protein by immunoprecipitation
experiments. As control, interaction with bax was also evaluated [30].
As reported in Figure 7, when immunoprecipitation of total extract
from M14 cells and its derivatives was carried out using an antibody
against Beclin-1 or bax proteins, and Western blot analysis was per-
formed using an antibody against amino acids 41 to 54 of bcl-2
(100), that specifically recognizes both wt and deleted bcl-2 protein
(Figure 7A), we found that, as expected, both bax and Beclin-1 proteins
bind bcl-2 wt protein. On the contrary, deletion of BH4 domain
strongly impairs the binding between bcl-2 and its interacting proteins
(Figure 7B). Because bcl-2 protein can form both heterodimers with
other proapoptotic members and homodimers [31], we determined
whether bcl-2 protein lacking the BH4 domain might bind to endoge-
nous bcl-2 to prevent it from binding to Beclin-1 or bax. To test this
hypothesis, we performed immunoprecipitation experiments using
an antibody that, recognizing an epitope of bcl-2 protein mapping at
the amino-terminus domain (N19), only immunoprecipitates bcl-2 wt
protein but not bcl-2/BH4del (Figure 7A). Using the two antibodies
specific for the different forms of bcl-2 protein, we showed that bcl-2/
BH4del protein was not present in a protein complex with the endog-
enous bcl-2 protein, demonstrating that full-length bcl-2 protein can-
not bind bcl-2 deleted protein. Similar data were obtained when
H1299 cells transiently expressing both EGFP–bcl-2 wt and bcl-2/
BH4del were immunoprecipitated with an EGFP antibody and then
analyzed by Western blot analysis using a bcl-2 antibody that specifi-
cally recognizes both wt and deleted bcl-2 proteins (data not shown).
Overall, these data indicate that bcl-2 protein blocks apoptosis [17]
(Figure W3B) and autophagy (Figure 1) through its BH4 domain,
being this domain critical for the interaction of bcl-2 protein with both
bax and Beclin-1 proteins.
Beclin-1 Knockdown Enhances Cell Proliferation in M14
Cells Expressing Bcl-2 Protein Lacking the BH4 Domain
To investigate whether Beclin-1 is necessary for tumor growth in-
hibition by bcl-2/BH4del protein in M14 cells, stable cell subclones
expressing control short hairpin (sh) RNA (BH4del-shControl)
or shRNA directed against the essential autophagy gene Beclin-1
(BH4del–shBeclin-1) were generated from cells expressing bcl-2/
BH4del (Figure 7B). Upon starvation, as a consequence of Beclin-1
knockdown, a reduction of both LC3B-II/LC3B-I ratio (Figure 8A)
and AVO-positive cells (Figure 8B) was observed in cells express-
ing bcl-2/BH4del when compared to bcl-2/BH4del cells expressing
shControl, thus indicating an attenuation of autophagy activation.
Knockdown of Beclin-1 also resulted in significant increase of in vitro
proliferation (Figure 8C ) and in long-term survival being the clono-
genic efficiency of bcl-2/BH4del cells enhanced from about 40% to
70% after Beclin-1 knockdown. According to in vitro results, Beclin-1
down-regulation rescued BH4-dependent inhibition of in vivo tumor
growth (Figure 8D), thus indicating that the effect of bcl-2/BH4del
protein on cell growth is strongly correlated with Beclin-1 expression,
being Beclin-1 required for the ability of bcl-2/BH4del to induce
autophagy and to modulate cell growth. To study the extent of con-
tribution of autophagy on cell proliferation reduction by bcl-2/BH4del
protein, we evaluated the effect of chloroquine treatment on in vitro
cell growth. As reported in Figure 8E , we found that chloroquine treat-
ment of M14 control and bcl-2 wt overexpressing cells had minimal or
no effects on cell proliferation and vitality, while it decreased prolifera-
tion and vitality of cells expressing bcl-2/BH4del. At day 7 of growth, a
nonsignificant reduction of about 2% and 15% was observed in control
and bcl-2 wt clones, respectively, while a significant reduction of about
30% (P < .05) was evidenced in bcl-2/BH4del overexpressing clones.
Finally, we evaluated whether endogenous Beclin-1 is required for
the ability of bcl-2/BH4del to induce autophagy and to modulate
cell growth. To address this issue, JR8 human melanoma and HT29
human colon carcinoma cells, both characterized by undetectable or
very low levels of endogenous bcl-2 [17] and Beclin-1 proteins (Fig-
ure 9A), were stably transfected with expression vectors for bcl-2 wt
or bcl-2/BH4del. As reported in Figure 9B, upon starvation HT29
cells were reluctant to induce AVO formation and localization of
LC3B-II to autophagosome membrane regardless bcl-2 protein status.
Moreover, removal of BH4 domain from bcl-2 protein in HT29 did
not affect cell proliferation, being in vitro (Figure 9C ) and in vivo
(Figure 9D) growth rate of control and bcl-2 wt overexpressing cells
Figure 7. Bcl-2 protein lacking the BH4 domain strongly impairs the
binding between bcl-2 and bax or Beclin-1. (A) Western blot analysis
of bcl-2, bax, and Beclin-1 proteins in total lysates of M14 control
cells (puro) and its derivatives overexpressing bcl-2 wt (Bcl-wt) or
deleted of BH4 domain (BH4del). (A) β-Actin is shown as loading
and transferring control. (B) Immunoprecipitation (IP) of whole-cell
lysates with the indicated antibodies against Beclin-1, bax, and
bcl-2. (A, B)Western blot analysis of bcl-2 expressionwas performed
using antibodies against amino acids 41 to 54 of bcl-2, which spe-
cifically recognizes both wt and deleted bcl-2 protein [bcl-2 (100)], or
against an epitope of bcl-2 protein mapping at the amino-terminus
domain that recognizes only the wt protein [bcl-2 (N19)].
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superimposable to that of cells expressing bcl-2/BH4del. Similar results
in terms of response to autophagic stimuli (data not shown) and tumor
growth (Figure 9, E and F) were also observed in melanoma line JR8
stably expressing bcl-2 wt or bcl-2/BH4del. Overall, these results in-
dicate that bcl-2 protein deleted of its BH4 domain does not play a
role on in vitro and in vivo growth of tumor cells with low level of
bcl-2 and Beclin-1 proteins.
Discussion
Bcl-2 protein plays an important role in several cell functions, includ-
ing autophagy. Unlikely, the relevance of various BH domains of bcl-2
protein in autophagy has been poorly investigated. By using oligo-
nucleotides antisense against bcl-2 mRNA, we have found that down-
regulation of bcl-2 was paralleled by activation of autophagic program.
More importantly, by using melanoma cells overexpressing bcl-2 protein
wt or deleted of its BH4 domain, previously characterized for their
effect on tumor angiogenesis and apoptosis [17], we have demonstrated
that forced expression of bcl-2/BH4del protein leads to a restricted
tumorigenicity. In particular, cells expressing bcl-2/BH4del showed a
reduction of in vitro cell proliferation, colony formation, and in vivo
tumor growth when compared to control and bcl-2–transfected cells.
Consistent with these results, a reduction of mitotic and proliferating
cells in bcl-2/BH4del–xenotransplanted tumors was observed. An in-
creased time of tumor appearance, indicating an effect on the early
stages of tumor growth, was also evidenced in bcl-2/BH4del–carrying
animals and paralleled by a reduced tumor incidence.
Interestingly, increased autophagy was found in vivo after forced
expression of bcl-2/BH4del protein, and this process, concomitant with
reduced proliferation, might explain the tumor growth delay observed
in bcl-2/BH4del–xenotransplanted tumors. For the first time, our data
show that BH4 domain of bcl-2 is involved in the autophagosome
formation and that autophagic flux is increased by BH4 domain re-
moval. Thus, it is plausible that in our experimental models at the
early stages of tumorigenesis bcl-2 protein lacking BH4 domain reg-
ulates tumor development by suppressing tumor growth through reg-
ulating cell proliferation, whereas at later stages BH4 domain deletion
may lead to cell death through autophagy induction.
The significance of our study is enhanced by the evidence that also
cleavage of bcl-2 protein by apoptotic proteases, generated in the cells
by stimuli such as H2O2 and CDDP, recapitulates some of the re-
sults obtained after ectopical introduction of bcl-2 devoid of its BH4
domain, such as up-regulation of autophagosome marker LC3B-II
and down-regulation of autophagic substrate p62/SQSTM1. The
use of the z-VAD-fmk pan-caspase inhibitor confirmed the caspase-
dependent cleavage of bcl-2 at the N-terminal domain, as previously
demonstrated [16,28,32], and supported the role of bcl-2 cleavage
in autophagy induction. In fact, z-VAD-fmk blocked the cleavage
of bcl-2 protein and the ability of CDDP to modulate the expres-
sion of autophagic proteins. We cannot exclude that besides bcl-2,
Figure 8. Beclin-1 down-regulation enhances cell proliferation of M14 cells expressing bcl-2 protein lacking the BH4 domain. (A) Western
blot analysis of LC3B-I/II and Beclin-1 protein expression and (B) AVOs in cells grown in complete media or under serum starvation
(48 hours), (C) in vitro cell proliferation, and (D) tumor volume calculated at day 24 after cell injection of M14 control (puro) and its deriva-
tive expressing bcl-2 deleted of BH4 domain (BH4del) stably expressing control shRNA (shControl) or an shRNA directed against Beclin-1
(shBeclin-1). (A, B) Representative experiments of three independent ones with similar results are shown. (A) β-Actin is shown as loading
and transferring control. (B) The percentage of the cells with prominent red fluorescence is shown. (D) A representative experiment ± SD
of two independent ones with similar results is shown. (E) Growth curves of M14 cells and its derivatives untreated or treated with
chloroquine (25 μM). (C, E) The results represent the average ± SD of three independent experiments. *P < .05, relative to control cells
(C, D), or untreated cells (E).
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other proteins can be cleaved and play a role in the activation of
autophagic process.
To the best of our knowledge, this is the first demonstration that
deletion of 36 residues at the N-terminus of bcl-2 protein does
reduce tumor growth. In agreement with the results demonstrating
that targeted down-regulation of bcl-2 results in cancer cell death
[14,21,26], our findings evidenced a novel mechanism of tumor
growth inhibition induced by affecting bcl-2 functions. By immuno-
precipitation experiments, we have demonstrated that BH4 do-
main is critical for the interaction of bcl-2 protein with both bax
Figure 9. Deletion of BH4 domain from bcl-2 protein in HT29 colon carcinoma and JR8 melanoma cells does not affect tumorigenicity.
(A) Western blot analysis of bcl-2 and Beclin-1 proteins, (C, E) in vitro cell proliferation, and (D, F) in vivo tumor growth of HT29 colon
carcinoma and JR8 melanoma cells stably transfected with empty vector (puro) or with vectors encoding wt (Bcl-2wt) or mutated bcl-2
protein (BH4del). (C, E) The results represent the average ± SD of three independent experiments. (A, D, F) Representative experiments
of two independent ones with similar results are shown. (B) AVOs and immunofluorescence staining of LC3B expression (red) in HT29
control (puro) and their derivatives overexpressing bcl-2 wt (Bcl-2wt) or deleted of BH4 domain (BH4del) grown for 48 hours in complete
medium or under serum starvation. Representative pictures are shown.
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and Beclin-1. We can speculate that the removal of the entire BH4
region from bcl-2 protein could alter the conformation of the
hydrophobic cleft composed by the BH1, BH2, and BH3 domains
[30], thus interfering with the functions of proteins involved in cell
death, such as the proapoptotic protein bax and the BH3-only protein
Beclin-1, a key player in autophagy process. Beclin-1 under normal
steady-state growth conditions is bound to various antiapoptotic mem-
bers of the bcl-2 family, including bcl-2. Besides, disruption or reduc-
tion of the interaction of the BH3 domain of Beclin-1 with the binding
hydrophobic pocket of bcl-2 protein formed by the BH1–3 domain, pro-
motes autophagy [25,33]. Moreover, BH3-mimetic compounds (ABT-
737), “BH3-only” proteins (i.e., BNIP3, Bad), c-Jun N-terminal kinases
(JNK)-mediated bcl-2 phosphorylation, and death-associated protein
kinase-induced phosphorylation of Beclin-1 have been demonstrated
to induce autophagy through disruption of such interaction [34–37].
The fact that 1) bcl-2 wt but not deleted of BH4 domain interacts
with Beclin-1, 2) down-regulation of Beclin-1 in M14 cells expressing
bcl-2/BH4del partially rescues cell proliferation and colony-forming
ability, and 3) overexpression of bcl-2 wt or truncated in the BH4
domain did not result in any in vitro and in vivo growth retardation
of the JR8 melanoma and HT29 colon carcinoma lines, both expres-
sing very low levels of Beclin-1, indicates an involvement of Beclin-1 in
the inhibitory effect of bcl-2/BH4del on in vivo tumor growth. Our
findings also evidenced that the full-length endogenous bcl-2 protein
fails to bind bcl-2 deleted protein, ruling out the hypothesis that bcl-2/
BH4del prevents bcl-2 binding to Beclin-1. However, other bcl-2–
interacting proteins might be also involved in BH4 domain function.
Noteworthy, when the bcl-2 Δα1 protein, lacking 22 residues at the
N-terminus and retaining the ability to bind Beclin-1 and to protect
from autophagic stimuli and losing the antiapoptotic properties of
bcl-2 [29], was expressed in M14 cells, tumor growth rate was super-
imposable to that of control xenografts, thus indicating that removal
of different lengths of N-terminus from bcl-2 protein can differently
affect in vitro and in vivo cell death and consequently tumor growth.
Because the two mutants we used differ for residues 23 to 36,
belonging to part of BH4 domain and a short part of the loop region,
we can speculate that the gain of function phenotype that we have
observed in bcl-2/BH4del may be the result of an interplay of these
residues with other functional domains of bcl-2 or with other proteins.
However, we cannot exclude that posttranslational modifications, such
as phosphorylation of serine/tyrosine residues within 23 to 36 amino
acid sequence of bcl-2, could be responsible of the difference observed
between bcl-2 Δα1 and bcl-2/BH4del expressing cells in terms of cell
death and tumor growth. Bcl-2 protein contains a number of possible
serine phosphorylation sites that play a regulatory role in its functions,
including serine 24 [38], serine 70 [39], and serine 87 [40], and these
posttranslational modifications could directly or indirectly affect the
interaction of bcl-2 with molecules involved in activation of cell death.
It is possible that the lacking of the potential phosphorylation site in
serine 24 in bcl-2/BH4del expressing cells could be responsible of
the novel proautophagic and tumor suppressor functions of bcl-2/
BH4del protein.
In conclusion, careful dissection of the biologic and biochemical
effects of bcl-2 wt or lacking different amino acidic regions in differ-
ent cell types may contribute to the understanding of the function of
this protein and the relevance of the various domains in its functions.
Our findings provide new insight into molecular mechanism of bcl-2
functions and an opportunity to develop new agents to promote tumor
cell death by interfering with BH4 domain functions. The targeting
of autophagic/apoptotic pathways by gene therapeutic or pharmaco-
logic strategies could represent a very promising option for the treat-
ment of cancer. Agents interfering with the critical residues of the
BH4 domain or expression of a bcl-2–modified protein in cancer
cells may provide a new strategy in cancer therapy by impairing bcl-2
function and inducing autophagy.
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Figure W1. (A) Western blot analysis of bcl-2 protein expression in M14 human melanoma cells treated with an oligonucleotide antisense
against bcl-2 mRNA (AS bcl-2) or with a control oligonucleotide sequence. Analysis was performed 48 hours after exposure to AS bcl-2 for
6 hours. β-Actin is shown as loading and transferring control. (B) Representative images of fluorescence microscopy of cells positive for
autophagosomal structures in M14 cells stably transfectedwith EGFP-LC3B vector treatedwith an AS bcl-2 or with a control oligonucleotide
sequence and grown as reported in A.
Figure W2. (A) Western blot analysis of bcl-2, p62/SQSTM1, PARP, and LC3B-I/II protein expression in floating (Fl) and adherent (Ad) M14
cells exposed to H2O2 and CDDP or after 6 days from seeding in high cell density condition. Two bands, indicative of the higher endogenous
full-length bcl-2 protein and a lower bcl-2 proteolytic fragment, were observed. (B) Western blot analysis of bcl-2, p62/SQSTM1, PARP, and
LC3B-I/II protein expression in pooled adherent and floating M14 cells exposed to CDDP in the presence or absence of the pan-caspase
inhibitor z-VAD-fmk. (A, B) One hundred micrograms of total proteins was loaded. Western blots, representative of three independent
experiments with similar results, are shown. β-Actin is shown as loading and transferring control.
Figure W3. Cytofluorimetric analysis of (A) cells in S phase of cell cycle by BrdU incorporation/propidium iodide (PI) staining and
(B) apoptosis by annexin V/PI staining in M14 control (puro) and its derivatives overexpressing bcl-2 wt (Bcl-2wt/37) or bcl-2 protein
deleted of BH4 domain (BH4del/6, BH4del/5). (B) Analysis was performed at days 4 and 8 after plating or after camptothecin treatment
(CPT, 0.5 μM, 24 hours), and the percentage of apoptotic cells (annexin V positive/PI negative) is reported.
